Michael Dube Sells 2,641 Shares of Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 2,641 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. The trade was a 3.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Intellia Therapeutics Stock Up 1.6%

NTLA traded up $0.28 during trading hours on Monday, reaching $17.84. 3,834,214 shares of the company’s stock traded hands, compared to its average volume of 5,666,633. The firm has a 50-day moving average price of $14.13 and a 200 day moving average price of $13.07. Intellia Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $28.25. The firm has a market capitalization of $2.49 billion, a PE ratio of -5.04 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The business had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. During the same quarter last year, the firm posted ($1.10) earnings per share. Equities analysts predict that Intellia Therapeutics, Inc. will post -3.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC raised its stake in Intellia Therapeutics by 154.1% in the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after buying an additional 55,118 shares in the last quarter. Woodline Partners LP purchased a new position in Intellia Therapeutics in the first quarter valued at about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after purchasing an additional 38,521 shares in the last quarter. Creative Planning raised its holdings in Intellia Therapeutics by 12.9% in the second quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after purchasing an additional 3,795 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Intellia Therapeutics by 47.4% during the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock valued at $315,000 after buying an additional 10,785 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on NTLA shares. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 15th. Citizens Jmp restated a “market outperform” rating and issued a $30.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Tuesday, April 21st. Chardan Capital boosted their price target on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, April 27th. Finally, Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a research note on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.46.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.